Description
Researchers study long-acting incretin receptor kinetics by tracking how the Dulaglutide peptide alters metabolic signaling. Designed as a structural analog to native GLP-1, this compound links directly with an IgG4 Fc fusion backbone to minimize renal filtration and enzymatic breakdown in laboratory environments.
Key Research Focus
Extended Pathway Kinetics: Helps specialists examine how heavy synthetic structures shield endocrine profiles from rapid degradation.
Glucose-Dependent Signaling: Allows researchers to monitor steady hormone patterns and insulin secretion mechanisms using this pure Dulaglutide peptide.
Cellular Longevity Data: Delivers clear, reproducible data on tissue preservation and glycemic stability markers during bench trials. You can review quality standards on our COA Verification Page.
Technical Specifications
| Specification | Details |
| Primary Target | GLP-1 Receptor Agonist (IgG4 Fc Fusion) |
| Documentation | COA verified peptides status included |
| Category | Metabolic Peptides & Peptide Bioregulators |
| Format | Sterile Lyophilized Powder |
Handling & Storage Guidelines
Storage Condition: Keep the dry vial hermetically sealed at -20°C for stable, long-term storage (protected from light).
Reconstitution & Handling: Reconstitute gently down the inside vial wall to avoid chain degradation. For clinical research literature on Dulaglutide, consult the open-access database on PubMed Dulaglutide Citations.
Usage Safety: Divide into single-use fractions post-reconstitution to prevent structural damage from repeated freeze-thaw cycles.
Research Disclaimer: This compound is synthesized strictly for laboratory research and development purposes. It is not intended for human therapeutic, diagnostic, or clinical use.
Reviews
There are no reviews yet.